Affimed To Present Preclinical Data On Bi- And Trispecific Immune Cell Engagers At ASH

HEIDELBERG, Germany, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that three of the Company's abstracts have been chosen for poster presentations at the 58 th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.

Poster Information 
AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation (Abstract #1764)
Session: 622. Lymphoma Biology - Non-Genetic Studies: Poster I
Date: Saturday, December 3, 2016: 5:30-7:30 p.m. (PT)
Location: Hall GH (San Diego Convention Center)
 
Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb ® AFM11 (Abstract #4130)
Session: 622. Lymphoma Biology - Non-Genetic Studies: Poster III
Date: Monday, December 5, 2016: 6:00-8:00 p.m. Pacific Time
Location: Hall GH (San Diego Convention Center)
 
Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma (Abstract #4513)
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III
Date: Monday, December 5, 2016: 6:00-8:00 p.m. Pacific Time
Location: Hall GH (San Diego Convention Center)

About AFM13

AFM13 is a bispecific NK-cell TandAb simultaneously targeting CD16A on NK-cells and CD30 on tumor cells. AFM13 is designed to treat CD30-positive malignancies including Hodgkin lymphoma (HL) and T-cell lymphoma (TCL) and is currently in Phase 2 studies in HL patients. Based on its appropriate safety profile, AFM13 is being developed both as monotherapy and in combination with other therapeutics such as our collaboration partner Merck's checkpoint inhibitor KEYTRUDA ®.

About AFM11

AFM11 is a bispecific T-cell TandAb simultaneously targeting CD3 on T-cells and CD19 on tumor cells. AFM11 is specifically designed to treat B-cell malignancies including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), in which CD19 is expressed at abnormally high levels. AFM11 is currently in Phase 1 clinical development for NHL and ALL.

If you liked this article you might like

These 7 Stocks Under $10 Are About to Break Out

8 Breakout Stocks Under $10 to Trade for Big Profits

These 5 Biotech Stocks Under $10 Are About to Break Out

5 Stocks Under $10 Set to Soar

Here's Why Affimed (AFMD) Stock is Popping Today